PT - JOURNAL ARTICLE AU - Huang, Yunxia AU - Wen, Zhuofeng AU - Luo, Hongbin AU - Liao, Yijie AU - Chen, Zisheng TI - Association between Cardiovascular Disease Risk and long COVID-19: A Systematic Review and Meta-analysis AID - 10.1101/2023.12.30.23300656 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.30.23300656 4099 - http://medrxiv.org/content/early/2023/12/31/2023.12.30.23300656.short 4100 - http://medrxiv.org/content/early/2023/12/31/2023.12.30.23300656.full AB - Objectivate To assess demographic characteristics and investigate the correlation between cardiovascular diseases and long COVID-19 patients.Methods Comprehensive details, encompassing the first author’s name, publication year, sample inclusion criteria, sample size, and demographic characteristics, including age and gender of participants, were systematically extracted from all incorporated studies. Meanwhile, the analysis encompassed the assessment of the risk associated with nineteen cardiovascular outcomes.Results A total of 3, 201 potentially eligible studies were initially identified for consideration. Following rigorous literature screening and quality control measures, eighteen studies, encompassing 46, 083, 975 patients, met the specified criteria. In comparison to the control cohort, our investigation unveiled a heightened risk of 19 cardiovascular outcomes associated with long COVID-19. Our meta-analysis revealed a pooled OR of 1.68 (95% CI 1.55-1.81) (I2 = 69.1%, p= 0.000) for the overall risk of cardiovascular outcomes, indicating an elevated risk of cardiovascular diseases in individuals affected by long COVID-19. While the heterogeneity was relatively high, it is essential to acknowledge that all studies inherently carry an unavoidable risk of bias, irrespective of their quality rating. Moreover, there appears to be no significant publication bias based on the funnel plot, Begg’s, and Egger’s tests. Sensitivity analysis did not reveal substantial alterations in the overall stability of the results.Conclusions Our meta-analysis substantiates that individuals afflicted with long COVID-19 face an elevated risk of developing cardiovascular diseases. Routine assessment of cardiac function is deemed essential for a long COVID-19 high-risk cardiovascular disease population. Timely interventions have the potential to mitigate the risk of cardiovascular diseases and associated mortality in this population.TRIAL REGISTRATION PROSPERO Identifier CRD42023455701Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:from pudmed , embase, web of science, cochrane, scopusI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online atThe research contributions presented in this article are detailed in the article/supplementary material; you can contact the relevant author for further information.WHOWorld Health Organization;HRHazard ratio;RRrisk ratio;ORodds ratio;CIconfidence interval;REMrandom-effects model;ACE2angiotensin-converting enzyme 2;SARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2 CoV;MESHMedical Subject Headings;NOSNewcastle-Ottawa Scale;FEMfixed-effect model;BMIBody Mass Index;ILinterleukin;